What Drugmakers Did Not Tell Volunteers in Alzheimer’s Trialsnews2024-10-23T14:19:56+00:00October 23rd, 2024|The New York Times|
Trump’s Takeover of the Republican Partynews2024-02-15T17:38:23+00:00February 15th, 2024|The New York Times|
Biogen Abandons Its Controversial Alzheimer’s Drug Aduhelmnews2024-01-31T19:10:58+00:00January 31st, 2024|The New York Times|
Un esperanzador experimento de ultrasonido para los tratamientos del cerebronews2024-01-17T08:00:22+00:00January 17th, 2024|The New York Times|
An Ultrasound Experiment Tackles a Giant Problem in Brain Medicinenews2024-01-10T10:01:37+00:00January 10th, 2024|The New York Times|
FDA Approves, Leqembi, New Treatment for Early Alzheimer’snews2023-01-06T22:58:48+00:00January 6th, 2023|The New York Times|
Congressional Investigation into Alzheimer’s Drug Aduhelm Faults the F.D.A. and Biogennews2022-12-29T19:54:35+00:00December 29th, 2022|The New York Times|
What A.L.S. and Alzheimer’s Drug Approvals Have in Commonnews2022-10-14T19:10:06+00:00October 14th, 2022|The New York Times|
Alzheimer’s Drug Slows Cognitive Decline in Key Studynews2022-09-28T13:42:59+00:00September 28th, 2022|The New York Times|
Biogen C.E.O. to Step Down Following Launch of Alzheimer’s Drug, Aduhelmnews2022-05-03T18:00:36+00:00May 3rd, 2022|The New York Times|
